Lupin receives approval from USFDA for Brexpiprazole Tablets
Brexpiprazole Tablets, 0.25 mg, 0.5 mg, 1 mg, 2 mg, 3 mg, and 4 mg, (RLD Rexulti) had estimated annual sales of US $1,575 million in the US (IQVIA MAT December 2022)
Brexpiprazole Tablets, 0.25 mg, 0.5 mg, 1 mg, 2 mg, 3 mg, and 4 mg, (RLD Rexulti) had estimated annual sales of US $1,575 million in the US (IQVIA MAT December 2022)
The approved product is indicated for the treatment of adult patients with Multiple myeloma, in combination with Dexamethasone
Twelve hospitals across India will be part of the network which will support the trial in India
The EIR was issued post the last inspection of the facility conducted from October 17, 2022 to October 29, 2022
She is a seasoned leader with nearly 30 years of business leadership and consulting experience with top companies such as Mckinsey and Co, Novartis Pharmaceuticals and Stryker India Pvt. Ltd.
The approval for Glycopyrrolate clears the path for more internally manufactured injectable products
With the recent sales force expansion and new product launches, we expect to be back to above-market growth
Profit after Tax stood at Rs. 106 crore as compared to Rs. 84 crore registering growth of 26%
DETAF would be a welcome new addition in the management of HIV infections and will be available for supplies to low- and middle-income countries
Multilateral collaborations will serve to strengthen knowledge sharing to formulate framework for accessible, affordable, and quality healthcare
Subscribe To Our Newsletter & Stay Updated